New pill could ease lupus kidney damage – trial underway
NCT ID NCT07363460
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental pill called HSK39297 for people with lupus nephritis, a kidney complication of lupus. About 105 adults will receive either 200 mg, 300 mg, or a placebo daily for several weeks. The main goal is to see if the drug reduces protein in the urine, a sign of kidney damage, and to check for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS (LN) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Nephrology, Zhong Da Hospital, Southeast University School of Medicine
RECRUITINGNanjing, Jiangsu, 210000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single infusion of reprogrammed immune cells quiet lupus kidney disease?
- Blood traps may reveal lupus kidney treatment success
- A simple blood marker may reveal hidden heart risks in lupus
- Can a gentler steroid dose protect children's kidneys without the harsh side effects?
- Could a diabetes drug shield kidneys in lupus?
- Experimental drug aims to protect kidneys in inflammatory diseases